Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast ButtonSwitch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Stay Informed: Medical and Research Updates
Connect With Us!
 

 

Pfizer Announces Findings from First of Four Phase III Clinical Studies for Bapineuzumab

Co-Primary Clinical Endpoints Not Met in Study of Patients with Alzheimer’s Disease Who Carry The ApoE4 Genotype

July 26, 2012

Source: Pfizer

Findings: Bapineuzumab IV (bapineuzumab) is an antibody that targets the toxic beta-amyloid protein. It is being tested for the treatment of mild-to-moderate Alzheimer's disease in four clinical trials led by Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI) and Pfizer, Inc. In one study led by Janssen AI (called study 302), it was reported that the participants who had the ApoE4 gene showed no discernible improvement in their cognitive performance or laboratory tests when treated with bapineuzumab as compared to those who received a placebo (non-bapineuzumab containing) treatment.

Significance: This particular drug candidate doesn't appear to be an effective treatment strategy for people who have Alzheimer's disease and are carrying the ApoE4 gene. However, these findings don't exclude the possibility that this drug could be an effective treatment for people without the ApoE4 gene variation. The results from three other phase III clinical studies on bapineuzumab treatment for Alzheimer's disease are still being analyzed and should be released before the end of this year. There is still hope that bapineuzumab may be shown to be effective for the estimated 70-75% of Americans who have Alzheimer's disease and don't have the ApoE4 gene.

For descriptions of all four clinical trials, including site locations, visit ClinicalTrials.gov:


Extension to Studies 301 and 302 (Long-Term Safety and Tolerability Study):

Press Release:

View all news updates for Alzheimer's disease


Disclaimer: The information provided in this section is a public service of the BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.

Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.

Shop for a Cause YouTube Twitter Connect With Us Pinterest Google+